Vanguard Group Inc. Has $60.75 Million Stock Holdings in WAVE Life Sciences Ltd. $WVE

Vanguard Group Inc. raised its holdings in shares of WAVE Life Sciences Ltd. (NASDAQ:WVE) by 13.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,573,746 shares of the company’s stock after purchasing an additional 433,910 shares during the quarter. Vanguard Group Inc. owned approximately 2.14% of WAVE Life Sciences worth $60,754,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH increased its position in WAVE Life Sciences by 11.6% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 411,494 shares of the company’s stock worth $6,995,000 after buying an additional 42,789 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in WAVE Life Sciences by 20.5% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 62,729 shares of the company’s stock worth $1,066,000 after buying an additional 10,683 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in WAVE Life Sciences by 32.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,124 shares of the company’s stock worth $138,000 after buying an additional 1,972 shares during the period. CWM LLC increased its position in WAVE Life Sciences by 6,729.0% during the 4th quarter. CWM LLC now owns 2,117 shares of the company’s stock worth $36,000 after buying an additional 2,086 shares during the period. Finally, Gainplan LLC bought a new position in WAVE Life Sciences during the 4th quarter worth $680,000. Institutional investors own 89.73% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of WAVE Life Sciences in a research report on Monday, April 20th. Bank of America lowered their price objective on WAVE Life Sciences from $38.00 to $21.00 and set a “buy” rating on the stock in a research report on Friday, March 27th. Wells Fargo & Company lowered their price objective on WAVE Life Sciences from $27.00 to $13.00 and set an “overweight” rating on the stock in a research report on Friday, March 27th. Wall Street Zen upgraded WAVE Life Sciences from a “strong sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Cantor Fitzgerald increased their price objective on WAVE Life Sciences from $34.00 to $41.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Fourteen equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, WAVE Life Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

WAVE Life Sciences Stock Down 1.3%

NASDAQ:WVE opened at $6.90 on Friday. The stock’s 50-day simple moving average is $8.92 and its 200 day simple moving average is $11.23. The firm has a market capitalization of $1.33 billion, a PE ratio of -6.51 and a beta of -1.32. WAVE Life Sciences Ltd. has a twelve month low of $5.02 and a twelve month high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Wednesday, April 29th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.21. The business had revenue of $38.25 million for the quarter, compared to analyst estimates of $8.45 million. WAVE Life Sciences had a negative return on equity of 56.76% and a negative net margin of 255.70%. On average, analysts anticipate that WAVE Life Sciences Ltd. will post -1.16 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Chris Francis sold 33,194 shares of the firm’s stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $15.05, for a total value of $499,569.70. Following the sale, the insider directly owned 61,867 shares of the company’s stock, valued at $931,098.35. This trade represents a 34.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 24.30% of the stock is owned by company insiders.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.